| He, Qiang |
NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3 |
|
|
| Recruiting | 4 | 466 | RoW | Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638 | The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd. | Renal Insufficiency, Chronic | 10/25 | 03/26 | | |
SCDB, NCT06422845: Peripheral Scoring Drug-coated Balloon in the Treatment of Hemodialysis Arteriovenous Fistula Stenosis |
|
|
| Recruiting | N/A | 328 | RoW | Dissolve AV Peripheral Scoring Drug-coated Balloon, Scoring Drug-coated Balloon | DK Medical Technology (Suzhou) Co., Ltd. | Arteriovenous Fistula Stenosis | 07/27 | 07/27 | | |
| Recruiting | N/A | 366 | Canada, RoW | | The George Institute, Peking University Institute of Nephrology | IgA Nephropathy, ESRD, Glomerulonephritis, Kidney Diseases | 07/27 | 07/27 | | |
| Xiangmin, Tong |
NCT05602792: A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 233 | RoW | T3011 | ImmVira Pharma Co. Ltd | Advanced Solid Tumor, Sarcoma, HNSCC, Breast Cancer, Esophagus Cancer, NSCLC, Non-melanoma Skin Cancer | 07/23 | 01/24 | | |
FIH, NCT05707325: Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies |
|
|
| Recruiting | 1 | 30 | RoW | engineered red blood cell | Westlake Therapeutics | Cancer, Solid Tumor, Hematologic Malignancy | 12/25 | 07/26 | | |
| Zongmao, Zhao |
NCT05913037: FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas |
|
|
| Recruiting | 3 | 162 | RoW | Test group (Group A): FCN-159 8 mg, orally, once daily;, Control group (Group B): Placebo, orally, once daily; | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Neurofibromatosis 1, Plexiform Neurofibroma, NF1 | 06/25 | 06/26 | | |
